|
US5672659A
(en)
|
1993-01-06 |
1997-09-30 |
Kinerton Limited |
Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
|
|
AU684498B2
(en)
|
1993-03-25 |
1997-12-18 |
Merck & Co., Inc. |
Inhibitor of vascular endothelial cell growth factor
|
|
US5595760A
(en)
|
1994-09-02 |
1997-01-21 |
Delab |
Sustained release of peptides from pharmaceutical compositions
|
|
JPH09154588A
(ja)
|
1995-10-07 |
1997-06-17 |
Toagosei Co Ltd |
Ｖｅｇｆ結合性ポリペプチド
|
|
US6100071A
(en)
|
1996-05-07 |
2000-08-08 |
Genentech, Inc. |
Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
|
|
JP3011144B2
(ja)
|
1997-07-31 |
2000-02-21 |
日本電気株式会社 |
光スキャナとその駆動方法
|
|
US7306799B2
(en)
|
1999-06-08 |
2007-12-11 |
Regeneron Pharmaceuticals, Inc. |
Use of VEGF inhibitors for treatment of eye disorders
|
|
US7303746B2
(en)
|
1999-06-08 |
2007-12-04 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating eye disorders with modified chimeric polypeptides
|
|
US7087411B2
(en)
|
1999-06-08 |
2006-08-08 |
Regeneron Pharmaceuticals, Inc. |
Fusion protein capable of binding VEGF
|
|
US7396664B2
(en)
|
1999-06-08 |
2008-07-08 |
Regeneron Pharmaceuticals, Inc. |
VEGF-binding fusion proteins and nucleic acids encoding the same
|
|
US7070959B1
(en)
|
1999-06-08 |
2006-07-04 |
Regeneron Pharmaceuticals, Inc. |
Modified chimeric polypeptides with improved pharmacokinetic properties
|
|
CN100523187C
(zh)
|
1999-06-08 |
2009-08-05 |
里珍纳龙药品有限公司 |
具有改善的药物动力学特性的修饰嵌合多肽
|
|
US6833349B2
(en)
*
|
1999-06-08 |
2004-12-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating inflammatory skin diseases
|
|
US7141607B1
(en)
|
2000-03-10 |
2006-11-28 |
Insite Vision Incorporated |
Methods and compositions for treating and inhibiting retinal neovascularization
|
|
JP2003529567A
(ja)
|
2000-03-10 |
2003-10-07 |
インサイト・ビジョン・インコーポレイテッド |
後眼部眼疾患を治療および予防する方法と組成物
|
|
EP1631317A2
(en)
|
2003-06-06 |
2006-03-08 |
Regeneron Pharmaceuticals, Inc. |
Use of vegf inhibitors for tumor regression
|
|
US7399612B2
(en)
|
2003-06-30 |
2008-07-15 |
Regeneron Pharmaceuticals, Inc. |
VEGF-binding fusion proteins and nucleic acids encoding the same
|
|
AR046510A1
(es)
|
2003-07-25 |
2005-12-14 |
Regeneron Pharma |
Composicion de un antagonista de vegf y un agente anti-proliferativo
|
|
US7582726B2
(en)
|
2003-11-10 |
2009-09-01 |
Ghc Research Development Corporation |
VEGF receptor antagonists
|
|
EP1753442A2
(en)
|
2004-06-10 |
2007-02-21 |
Regeneron Pharmaceuticals, Inc. |
Method of administering and using vegf inhibitors for the treatment of human cancer
|
|
US20080292628A1
(en)
*
|
2004-10-12 |
2008-11-27 |
Amprotein Corporation |
Chimeric Protein
|
|
US8048418B2
(en)
|
2004-10-29 |
2011-11-01 |
Regeneron Pharmaceuticals, Inc. |
Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
|
|
US7303748B2
(en)
|
2005-02-02 |
2007-12-04 |
Regeneron Pharmaceuticals, Inc. |
Method of treating eye injury with local administration of a VEGF inhibitor
|
|
AU2006213856B2
(en)
|
2005-02-11 |
2011-03-17 |
Regeneron Pharmaceuticals, Inc. |
Therapeutic combination of a VEGF antagonist (VEGF trap) and an anti-hypertensive agent
|
|
US20070166388A1
(en)
|
2005-02-18 |
2007-07-19 |
Desai Neil P |
Combinations and modes of administration of therapeutic agents and combination therapy
|
|
SI1853250T1
(sl)
|
2005-02-18 |
2012-01-31 |
Abraxis Bioscience Llc |
Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija
|
|
US8735394B2
(en)
|
2005-02-18 |
2014-05-27 |
Abraxis Bioscience, Llc |
Combinations and modes of administration of therapeutic agents and combination therapy
|
|
CN102614134B
(zh)
|
2005-03-25 |
2016-09-07 |
瑞泽恩制药公司 |
Vegf拮抗剂制剂
|
|
EP1917024A2
(en)
|
2005-08-12 |
2008-05-07 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating diseases with a vegf antagonist
|
|
AU2006279541A1
(en)
|
2005-08-15 |
2007-02-22 |
The Regents Of The University Of California |
VEGF-activated FAS ligands
|
|
CN100471872C
(zh)
*
|
2005-11-04 |
2009-03-25 |
余波 |
包含vegf受体片段的优化融合蛋白质及其医疗应用
|
|
DK1962895T3
(da)
|
2005-12-16 |
2013-03-04 |
Regeneron Pharma |
TERAPEUTISK ANVENDELSE AF EN Dll4-ANTAGONIST OG EN VEGF-HÆMMER TIL HÆMNING AF TUMORVÆKST
|
|
US7354582B2
(en)
|
2006-03-10 |
2008-04-08 |
Regeneron Pharmaceuticals, Inc. |
Use of VEGF antagonists for the treatment of malignant gliomas
|
|
HRP20150884T1
(hr)
|
2006-03-21 |
2015-09-25 |
Genentech, Inc. |
Kombinacijska terapija koja ukljuäśuje antagoniste alfa5beta1
|
|
US7608261B2
(en)
|
2006-06-16 |
2009-10-27 |
Regeneron Pharmacuticals, Inc. |
VEGF antagonist formulations suitable for intravitreal administration
|
|
MX2009006202A
(es)
|
2006-12-11 |
2009-06-22 |
Genentech Inc |
Composiciones y metodos para el tratamiento de neoplasma.
|
|
CN101205252A
(zh)
|
2006-12-14 |
2008-06-25 |
上海中信国健药业有限公司 |
可溶性vegfr双功能融合受体、其制备方法及用途
|
|
CL2008002782A1
(es)
|
2007-09-21 |
2009-07-31 |
Genentech Inc |
Anticuerpo anti-bv8 neutralizante; composicion que lo comprende; y su uso para tratar tumores en humanos previamente tratados con un antagonista del factor de crecimiento endotelial vascular.
|
|
CN101575379B
(zh)
|
2008-05-09 |
2012-05-30 |
上海抗体药物国家工程研究中心有限公司 |
可溶性vegfr双功能融合受体、其制备方法及用途
|
|
WO2010067339A2
(en)
*
|
2008-12-11 |
2010-06-17 |
Korea Advanced Institute Of Science And Technology |
Fusion protein capable of binding vegf-a and tnf-alpha
|
|
CN101838329A
(zh)
*
|
2009-03-18 |
2010-09-22 |
嘉和生物药业有限公司 |
抗血管新生融合蛋白
|
|
KR101248912B1
(ko)
*
|
2009-12-31 |
2013-03-29 |
한양대학교 산학협력단 |
항혈관신생 활성을 가지는 재조합 아데노바이러스
|
|
PL2601214T3
(pl)
|
2010-08-06 |
2018-05-30 |
Genzyme Corporation |
Kompozycje antagonistyczne wobec VEGF oraz ich zastosowania
|
|
KR20260004598A
(ko)
|
2011-01-13 |
2026-01-08 |
리제너론 파아마슈티컬스, 인크. |
혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
|
|
CN102219859B
(zh)
|
2011-05-20 |
2012-09-12 |
烟台荣昌生物工程有限公司 |
拮抗血管新生诱导因子的融合蛋白及其用途
|
|
WO2013082511A1
(en)
|
2011-12-02 |
2013-06-06 |
Genentech, Inc. |
Methods for overcoming tumor resistance to vegf antagonists
|
|
KR20140114415A
(ko)
|
2012-01-13 |
2014-09-26 |
제넨테크, 인크. |
Vegf 길항제로의 치료를 위한 환자를 확인하기 위한 생물학적 마커
|
|
WO2013152351A2
(en)
*
|
2012-04-06 |
2013-10-10 |
The Trustees Of Columbia University In The City Of New York |
Fusion polypeptides and methods of use thereof
|
|
CN102924604A
(zh)
*
|
2012-11-01 |
2013-02-13 |
中国人民解放军军事医学科学院生物工程研究所 |
重组血管内皮生长因子受体及其编码基因与应用
|
|
EP2916827B1
(en)
|
2012-11-08 |
2020-06-10 |
Clearside Biomedical Inc. |
Methods for the treatment of ocular disease in human subjects
|
|
EP2935589A1
(en)
|
2012-12-18 |
2015-10-28 |
Novartis AG |
Compositions and methods that utilize a peptide tag that binds to hyaluronan
|
|
RU2692652C2
(ru)
|
2013-03-13 |
2019-06-25 |
Джензим Корпорейшн |
Слитые белки, содержащие связывающие pdgf и vegf части, и способы их применения
|
|
WO2015000181A1
(zh)
|
2013-07-05 |
2015-01-08 |
华博生物医药技术（上海）有限公司 |
新型重组融合蛋白及其制法和用途
|
|
JP2016531149A
(ja)
|
2013-09-11 |
2016-10-06 |
ニューロテック ユーエスエー， インコーポレイテッド |
カプセル化細胞療法カートリッジ
|
|
CN105026433B
(zh)
|
2014-01-24 |
2018-10-19 |
上海恒瑞医药有限公司 |
VEGF与PDGFRβ双特异性融合蛋白及其用途
|
|
JP6071099B1
(ja)
|
2014-01-25 |
2017-02-01 |
ツェンドゥー カンホン バイオテクノロジーズ カンパニー リミテッド |
血管の新生又は成長を抑制する融合タンパク質及びその用途
|
|
KR101819135B1
(ko)
|
2014-03-18 |
2018-01-18 |
한국과학기술원 |
당화 vegf 디코이 수용체 융합 단백질
|
|
RU2702748C2
(ru)
|
2014-05-12 |
2019-10-11 |
Формикон Аг |
Предварительно заполненный пластиковый шприц, содержащий антагонист vegf
|
|
AU2015318207B2
(en)
|
2014-09-16 |
2021-11-04 |
Regeneron Pharmaceuticals, Inc. |
Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer
|
|
US10206910B2
(en)
|
2014-11-07 |
2019-02-19 |
Lam Therapeutics, Inc. |
Apilimod for use in the treatment of renal cancer
|
|
TWI738632B
(zh)
|
2014-11-07 |
2021-09-11 |
瑞士商諾華公司 |
穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
|
|
US20160144025A1
(en)
|
2014-11-25 |
2016-05-26 |
Regeneron Pharmaceuticals, Inc. |
Methods and formulations for treating vascular eye diseases
|
|
US10894083B2
(en)
|
2015-01-28 |
2021-01-19 |
Pfizer Inc. |
Stable aqueous anti-vascular endothelial growth factor (VEGF) antibody formulation
|
|
CA2981745C
(en)
|
2015-04-07 |
2021-11-02 |
Zimmer, Inc. |
Convertible glenoid
|
|
ES2797901T3
(es)
|
2015-06-28 |
2020-12-04 |
Allgenesis Biotherapeutics Inc |
Proteínas de fusión para la inhibición de angiogénesis
|
|
CN108290004A
(zh)
|
2015-11-18 |
2018-07-17 |
福尔密孔股份公司 |
含有vegf拮抗剂的预填充塑料注射器
|
|
KR101685532B1
(ko)
*
|
2016-04-26 |
2016-12-13 |
한국프라임제약주식회사 |
혈관내피성장인자 수용체 융합단백질
|
|
EP3412288A1
(en)
|
2017-06-08 |
2018-12-12 |
Galderma Research & Development |
Vegf inhibitors for use for preventing and/or treating acne
|
|
CN111032092A
(zh)
|
2017-06-30 |
2020-04-17 |
韩国科学技术院 |
Vegf-grab蛋白与药物的缀合物及其用途
|
|
MA50174A
(fr)
|
2017-09-18 |
2020-07-29 |
Amgen Inc |
Formules de protéines de fusion vegfr-fc
|
|
CN109575140B
(zh)
|
2017-09-29 |
2021-02-23 |
北京比洋生物技术有限公司 |
靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途
|
|
JP7536640B2
(ja)
|
2017-11-17 |
2024-08-20 |
アムジエン・インコーポレーテツド |
ＶＥＧＦＲ－Ｆｃ融合タンパク質製剤
|
|
FI3743091T3
(fi)
|
2018-01-26 |
2025-01-03 |
Univ California |
Menetelmät ja koostumukset verisuoniperäisten sairauksien hoitoon käyttämällä anti-vegf vaikuttavia aineita
|
|
CN111699004A
(zh)
|
2018-02-06 |
2020-09-22 |
豪夫迈·罗氏有限公司 |
眼科疾病的治疗
|
|
US11103552B2
(en)
|
2018-05-10 |
2021-08-31 |
Regeneron Pharmaceuticals, Inc. |
High concentration VEGF receptor fusion protein containing formulations
|
|
WO2021108255A1
(en)
|
2019-11-25 |
2021-06-03 |
The Regents Of The University Of California |
Long-acting vegf inhibitors for intraocular neovascularization
|